[HTML][HTML] Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and …
antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and …
COVID-19 associated pediatric vasculitis: A systematic review and detailed analysis of the pathogenesis
ED Batu, S Sener, S Ozen - Seminars in Arthritis and Rheumatism, 2022 - Elsevier
Abstract Objectives Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, has
opened a new era in the practice of pediatric rheumatology since it has been associated …
opened a new era in the practice of pediatric rheumatology since it has been associated …
Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …
characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against …
[HTML][HTML] Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency …
IM Otani, HK Lehman, AM Jongco, LR Tsao… - Journal of Allergy and …, 2022 - Elsevier
Secondary hypogammaglobulinemia (SHG) is characterized by reduced immunoglobulin
levels due to acquired causes of decreased antibody production or increased antibody loss …
levels due to acquired causes of decreased antibody production or increased antibody loss …
EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update
B Hellmich, B Sanchez-Alamo, JH Schirmer… - Annals of the …, 2024 - ard.bmj.com
Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …
Circulating Calprotectin (cCLP) in autoimmune diseases
M Manfredi, L Van Hoovels, M Benucci, R De Luca… - Autoimmunity …, 2023 - Elsevier
Background and aim Calprotectin (CLP) is a heterodimeric complex formed by two S100
proteins (S100A8/A9), which plays a pivotal role in innate immunity. Due to its intrinsic …
proteins (S100A8/A9), which plays a pivotal role in innate immunity. Due to its intrinsic …
[HTML][HTML] Eosinophilic granulomatosis with polyangiitis–advances in pathogenesis, diagnosis, and treatment
J Fijolek, E Radzikowska - Frontiers in Medicine, 2023 - frontiersin.org
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare disease characterized by
eosinophil-rich granulomatous inflammation and necrotizing vasculitis, predominantly …
eosinophil-rich granulomatous inflammation and necrotizing vasculitis, predominantly …
[HTML][HTML] Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double …
TM Maher, VA Tudor, P Saunders… - The Lancet …, 2023 - thelancet.com
Background Rituximab is often used as rescue therapy in interstitial lung disease (ILD)
associated with connective tissue disease (CTD), but has not been studied in clinical trials …
associated with connective tissue disease (CTD), but has not been studied in clinical trials …
ANCA associated vasculitis subtypes: recent insights and future perspectives
K Austin, S Janagan, M Wells… - Journal of …, 2022 - Taylor & Francis
The ANCA associated vasculitides (AAVs) affect a range of internal organs including ear
nose and throat, respiratory tract, kidneys, skin and nervous system. They include …
nose and throat, respiratory tract, kidneys, skin and nervous system. They include …